Füsun Erdenen1, Hülya Güngel2, Esma Altunoğlu1, Duygu Şak1, Cüneyt Müderrisoğlu1, Atakan Koro3, Pınar Akça Güler2, Muzaffer Ece Hakan Sahin1, Gonul Simsek4, Hafize Uzun5. 1. 1 Internal Medicine Clinic, lstanbul Education and Research Hospital , Istanbul, Turkey . 2. 2 Ophtalmology Clinic, lstanbul Education and Research Hospital , Istanbul, Turkey . 3. 3 Department of Biochemistry, lstanbul Education and Research Hospital , Istanbul, Turkey . 4. 4 Department of Physiology, Cerrahpasa Medical Faculty, Istanbul University , Istanbul, Turkey . 5. 5 Department of Biochemistry, Cerrahpasa Medical Faculty, Istanbul University , Istanbul, Turkey .
Abstract
BACKGROUND: Diabetic retinopathy (DR) is mainly caused by metabolic factors, vascular inflammation, and endothelial dysfunction. We aimed to evaluate the relationship of DR with inflammatory and biochemical alterations in type 2 diabetics. METHODS: A total of 89 diabetic patients with retinopathy [(DR (+) (n = 30)], without retinopathy [(DR (-) (n = 32)], and 27 control subjects were involved in the study. Demographic properties, biochemical values, ophtalmologic evaluation, C-reactive protein (CRP), and pentraxin-3 (PTX-3) levels were recorded. RESULTS: There was significant difference between controls, DR (-) and DR (+) groups with regard to serum PTX-3 levels. Control group had the lowest and DR (+) group revealed the highest PTX-3 levels. Severity of retinopathy was not related with CRP or PTX-3 levels. Duration of diabetes was longer, systolic blood pressure (SBP) and urinary albumin-creatinine ratio (UACR) were significantly higher in DR (+) subjects than DR (-) subjects. Multivariate analysis revealed that PTX-3 level and SBP were the variables that had a significant effect on DR (P = 0.002, OR = 1.61, and P = 0.021, OR = 1.06, respectively). CONCLUSIONS: Plasma PTX-3 levels may be a valuable predictor of DR-like factors such as duration of diabetes, hypertension, and UACR. Although inflammation has an important role in DR, we think that biomarkers reflecting inflammation is not sufficient to predict development and progression of DR; but follow up with PTX-3 levels along with ophthalmological evaluation may be useful. A single determination may not reflect the variations over time, so repeat measures may provide knowledge if PTX-3 is just a biomarker or has a causal role.
BACKGROUND:Diabetic retinopathy (DR) is mainly caused by metabolic factors, vascular inflammation, and endothelial dysfunction. We aimed to evaluate the relationship of DR with inflammatory and biochemical alterations in type 2 diabetics. METHODS: A total of 89 diabeticpatients with retinopathy [(DR (+) (n = 30)], without retinopathy [(DR (-) (n = 32)], and 27 control subjects were involved in the study. Demographic properties, biochemical values, ophtalmologic evaluation, C-reactive protein (CRP), and pentraxin-3 (PTX-3) levels were recorded. RESULTS: There was significant difference between controls, DR (-) and DR (+) groups with regard to serum PTX-3 levels. Control group had the lowest and DR (+) group revealed the highest PTX-3 levels. Severity of retinopathy was not related with CRP or PTX-3 levels. Duration of diabetes was longer, systolic blood pressure (SBP) and urinary albumin-creatinine ratio (UACR) were significantly higher in DR (+) subjects than DR (-) subjects. Multivariate analysis revealed that PTX-3 level and SBP were the variables that had a significant effect on DR (P = 0.002, OR = 1.61, and P = 0.021, OR = 1.06, respectively). CONCLUSIONS: Plasma PTX-3 levels may be a valuable predictor of DR-like factors such as duration of diabetes, hypertension, and UACR. Although inflammation has an important role in DR, we think that biomarkers reflecting inflammation is not sufficient to predict development and progression of DR; but follow up with PTX-3 levels along with ophthalmological evaluation may be useful. A single determination may not reflect the variations over time, so repeat measures may provide knowledge if PTX-3 is just a biomarker or has a causal role.
Entities:
Keywords:
C-reactive protein; diabetic retinopathy; pentraxin-3; type 2 diabetes mellitus; urinary albumin creatinine ratio
Authors: Matteo Stravalaci; Mariantonia Ferrara; Varun Pathak; Francesca Davi; Barbara Bottazzi; Alberto Mantovani; Reinhold J Medina; Mario R Romano; Antonio Inforzato Journal: Front Pharmacol Date: 2022-01-07 Impact factor: 5.810